- Home
- CCEL vs OTLK Comparison
CCEL vs OTLK Comparison
Compare CCEL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- OTLK
- Stock Information
- Founded
- CCEL 1989
- OTLK 2010
- Country
- CCEL United States
- OTLK United States
- Employees
- CCEL N/A
- OTLK N/A
- Industry
- CCEL Managed Health Care
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCEL Health Care
- OTLK Health Care
- Exchange
- CCEL Nasdaq
- OTLK Nasdaq
- Market Cap
- CCEL 51.9M
- OTLK 38.7M
- IPO Year
- CCEL 1997
- OTLK 2016
- Fundamental
- Price
- CCEL $6.45
- OTLK $1.20
- Analyst Decision
- CCEL Strong Buy
- OTLK Strong Buy
- Analyst Count
- CCEL 1
- OTLK 5
- Target Price
- CCEL $8.50
- OTLK $10.20
- AVG Volume (30 Days)
- CCEL 14.8K
- OTLK 373.9K
- Earning Date
- CCEL 04-14-2025
- OTLK 05-14-2025
- Dividend Yield
- CCEL 4.03%
- OTLK N/A
- EPS Growth
- CCEL N/A
- OTLK N/A
- EPS
- CCEL 0.05
- OTLK N/A
- Revenue
- CCEL $31,986,106.00
- OTLK N/A
- Revenue This Year
- CCEL $2.21
- OTLK N/A
- Revenue Next Year
- CCEL $0.98
- OTLK $288.46
- P/E Ratio
- CCEL $125.37
- OTLK N/A
- Revenue Growth
- CCEL 2.05
- OTLK N/A
- 52 Week Low
- CCEL $5.75
- OTLK $0.87
- 52 Week High
- CCEL $9.50
- OTLK $9.98
- Technical
- Relative Strength Index (RSI)
- CCEL 44.92
- OTLK 34.06
- Support Level
- CCEL $6.13
- OTLK $1.15
- Resistance Level
- CCEL $6.65
- OTLK $1.31
- Average True Range (ATR)
- CCEL 0.32
- OTLK 0.12
- MACD
- CCEL 0.04
- OTLK -0.01
- Stochastic Oscillator
- CCEL 63.04
- OTLK 20.45
Stock Price Comparison Chart: CCEL vs OTLK
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.